Hepatitis C Newsletter
Mild alcohol consumption is not associated with increased fibrosis in patients with chronic hepatitis C. Cheung O, Sterling RK, Salvatori J, et al. J Clin Gastroenterol. 2011 Jan;45(1): 76-82.
Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. Chayama K, Hayes CN, Yoshioka K, et al. J Gastro-enterol. 2011 Jan 19. [Epub ahead of print]
Clinical Significance of Perihepatic Lymphadenopathy in Patients with Chronic Hepatitis C Infection. Tavakoli-Tabasi S, Ninan S. Dig Dis Sci. 2011 Jan 23. [Epub ahead of print]
Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. Trapero-Marugán M, Mendoza J, Chaparro M, et al. World J Gastroenterol. 2011 Jan 28;17(4):493-8.
Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in Patients With Genotype 2 and 3 Chronic Hepatitis C. Manns M, Zeuzem S, Sood A, et al. J Hepatol. 2011 Jan 12. [Epub ahead of print]
U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for "Difficult-to-Treat" HCV Genotype 1 Patients. Ho SB, Aqel B, Dieperink E, Liu S, et al. Dig Dis Sci. 2011 Jan 11. [Epub ahead of print]
Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Lawitz E, Godofsky E, Rouzier R, et al. Antiviral Res. 2011 Jan 19. [Epub ahead of print]
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Thompson AJ, Santoro R, Piazzolla V, et al. Hepatology. 2011 Feb;53(2):389-95. doi: 10.1002/hep.24068. Epub 2011 Jan 10.
Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver. Ryan MC, Desmond PV, Slavin JL, Congiu M. J Viral Hepat. 2011 Jan;18(1):53-60. doi: 10.1111/j.1365-2893.2010.01283.x.
A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease. Washburn ML, Bility MT, Zhang L, et al. Gastroenterology. 2011 Jan 12. [Epub ahead of print]
The Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families. Murakami Y, Toyoda H, Tanaka M, et al. PLoS One. 2011 Jan 24;6(1):e16081.
Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol.
Teissier E, Zandomeneghi G, Loquet A, et al. PLoS One. 2011 Jan 25;6(1):e15874.
Synonymous mutations in the core gene are linked to unusual serological profile in hepatitis C virus infection. Budkowska A, Kakkanas A, Nerrienet E, et al. PLoS One. 2011 Jan 6;6(1):e15871.
Extracellular hepatitis C virus core protein activates STAT3 in human onocyte/ macrophage/dendritic cells via an IL-6 autocrine pathway. Tacke RS, Tosello-Trampont A, Nguyen V, Mullins DW, Hahn YS. J Biol Chem. 2011 Jan 31. [Epub ahead of print]
Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients.
Macías J, Mira J, Gilabert I, et al. HIV Med. 2011 Jan;12(1):14-21. doi: 10.1111/j.1468-1293.2010.00836.x.
Hepatitis C virus treatment rates and outcomes in HIV/hepatitis C virus co-infected individuals at an urban HIV clinic. Murray MC, Barrios R, Zhang W, et al. Eur J Gastroenterol Hepatol. 2011 Jan;23(1):45-50.
Down-regulation of intra-hepatic T-cell signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver disease. Berzsenyi MD, Woollard DJ, McLean CA, et al. J Hepatol. 2011 Jan 22. [Epub ahead of print]
HCV-Specific T cell Responses in HIV/HCV coinfected patients on HAART are comparable to those observed in HCV-monoinfected individuals. Rallón NI, Soriano V, Restrepo C, et al. J Acquir Immune Defic Syndr. 2011 Jan 28. [Epub ahead of print]
Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. Blanco F, Barreiro P, Ryan P, et al. J Viral Hepat. 2011 Jan;18(1):11-6. doi: 10.1111/j.1365-2893.2009.01261.x.
Comparison of HIV-, HBV-, HCV- and Co-Infection Prevalence between Chinese and Burmese Intravenous Drug Users of the China-Myanmar Border Region. Zhou YH, Liu FL, Yao ZH, Duo L, Li H, Sun Y, Zheng YT. PLoS One. 2011 Jan 21;6(1):e16349.
Patterns and Characteristics of Hepatitis C Transmission Clusters among HIV-Positive and HIV-Negative Individuals in the Australian Trial in Acute Hepatitis C. Matthews GV, Pham ST, Hellard M, et al. Clin Infect Dis. 2011 Jan 31. [Epub ahead of print]
Incident Hepatitis C Virus Infection among US HIV-Infected Men Enrolled in Clinical Trials. Taylor LE, Holubar M, Wu K, et al. Clin Infect Dis. 2011 Jan 31. [Epub ahead of print]
HIV/hepatitis C virus and HIV/hepatitis B virus coinfections protect against antiretroviral-related hyperlipidaemia. Diong C, Raboud J, Li M, Cooper C; the Ontario HIV Treatment Network Cohort Study Team. HIV Med. 2011 Jan 18. doi: 10.1111/j.1468-1293.2010.00897.x. [Epub ahead of print]
In-vitro antiviral activity of Solanum nigrum against Hepatitis C Virus. Javed T, Ashfaq UA, Riaz S, Rehman S, Riazuddin S. Virol J. 2011 Jan 19;8(1):26. [Epub ahead of print]
Prevalence of hepatitis B virus and hepatitis C virus among blood donors at a tertiary care hospital in India: a five-year study. Meena M, Jindal T, Hazarika A. Transfusion. 2011 Jan;51(1):198-202. doi: 10.1111/j.1537-2995.2010.02801.x.
Vietnamese community screening for hepatitis B virus and hepatitis C virus. Kallman JB, Tran S, Arsalla A, et al. J Viral Hepat. 2011 Jan;18(1):70-6. doi: 10.1111/j.1365-2893.2010.01278.x.
Needle exchange as a safe haven in an unsafe world. MacNeil J, Pauly B. Drug Alcohol Rev. 2011 Jan;30(1):26-32. doi: 10.1111/j.1465-3362.2010.00188.x.
Changes in Blood-borne Infection Risk Among Injection Drug Users. Mehta SH, Astemborski J, Kirk GD, et al. J Infect Dis. 2011 Mar;203(5):587-94. Epub 2011 Jan 31.
Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates).
Almasio PL, Babudieri S, Barbarini G, et al. Dig Liver Dis. 2011 Jan 20. [Epub ahead of print]
The Role of Patient Religiosity in the Evaluation and Treatment Outcomes for Chronic HCV Infection. Raghavan R, Ferlic-Stark L, Clarke C, Rungta M, Goodgame R. J Relig Health. 2011 Jan 19. [Epub ahead of print]
Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Cho LY, Yang JJ, Ko KP, et al. Int J Cancer. 2011 Jan 1;128(1):176-84. doi: 10.1002/ijc.25321.
Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer.
McGivern DR, Lemon SM. Oncogene. 2011 Jan 24. [Epub ahead of print]
Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. El-Serag HB, Kramer JR, Chen GJ, et al. Gut. 2011 Jan 21. [Epub ahead of print]
Chemoprevention of hepatocellular carcinoma in chronic hepatitis C. Morgan TR. Recent Results Cancer Res. 2011;188:85-99.
Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Davila JA, Henderson L, Kramer JR, et al. Ann Intern Med. 2011 Jan 18;154(2):85-93.
A Comparison of Prognosis between Patients with Hepatitis B and C Virus-related Hepatocellular Carcinoma Undergoing Resection Surgery. Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. World J Surg. 2011 Jan 5. [Epub ahead of print]